GlassScriptPhysician profile
Luis J Echarte
NPI 1043232028
$4,184.40
in general payments reported to CMS, 2019-2025
35 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,367 · 2020: $436 · 2021: $457 · 2022: $722 · 2023: $361 · 2024: $315 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $999.82 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $846.29 | 2019-2025 | Trelegy Ellipta, Shingrix, Nucala |
| Regeneron Healthcare Solutions, INC. | $297.39 | 2019-2023 | Dupixent |
| Mylan Specialty L.P. | $274.39 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.88 | 2019-2022 | |
| Genzyme Corporation | $234.22 | 2021-2025 | |
| Philips North America LLC | $184.72 | 2019-2023 | |
| Insmed, INC. | $156.72 | 2019-2025 | Arikayce |
| Baxter Healthcare | $152.16 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Volara System |
| Mallinckrodt Hospital Products INC. | $88.74 | 2021-2023 | Acthar |
| Pfizer INC. | $82.08 | 2019-2024 | |
| Genentech USA, INC. | $72.68 | 2019 | |
| United Therapeutics Corporation | $72.07 | 2019-2021 | |
| Circassia INC. | $50.99 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $50.08 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $47.56 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $39.90 | 2025 | |
| Electromed, INC. | $34.97 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $28.77 | 2019 | |
| Lilly USA, LLC | $24.88 | 2025 | Zepbound, Mounjaro |
| Viatris Specialty LLC | $20.16 | 2025 | Yupelri |
| Inspire Medical Systems, INC. | $20.12 | 2025 | Inspire |
| Amgen INC. | $20.07 | 2025 | Tezspire |
| Redhill Biopharma INC. | $18.91 | 2020 | |
| Resmed Corp | $18.83 | 2019 | |
| Sanofi Pasteur INC. | $17.62 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.57 | 2020 | |
| Shire North American Group INC | $16.41 | 2019 | |
| Amarin Pharma, INC. | $13.88 | 2019 | |
| Phadia US INC. | $13.86 | 2022 | |
| Merck Sharp & Dohme LLC | $12.70 | 2020 | |
| Advanced Respiratory, INC | $11.96 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Echarte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.